Systemic Chemokine Levels with “Gut-Specific” Vedolizumab in Patients with Inflammatory Bowel Disease—A Pilot Study

Vedolizumab, a gut-specific biological treatment for inflammatory bowel disease (IBD), is an antibody that binds to the α(4)β(7) integrin and blocks T-cell migration into intestinal mucosa. We aimed to investigate chemokine levels in serum of IBD-patients treated with vedolizumab. In this pilot stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Zwicker, Stephanie, Lira-Junior, Ronaldo, Höög, Charlotte, Almer, Sven, Boström, Elisabeth A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5578211/
https://www.ncbi.nlm.nih.gov/pubmed/28829369
http://dx.doi.org/10.3390/ijms18081827

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5578211/
https://www.ncbi.nlm.nih.gov/pubmed/28829369
http://dx.doi.org/10.3390/ijms18081827

Ejemplares similares